Analysed VERASTEM INC (VSTM:NASDAQ) News Sources
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
10-04-2026
yahoo.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-04-2026
yahoo.com
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
17-03-2026
yahoo.com
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
17-03-2026
yahoo.com
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
11-03-2026
yahoo.com
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ...
05-03-2026
yahoo.com
What is the current price of VERASTEM INC (VSTM:NASDAQ)?
The current price of VERASTEM INC (VSTM:NASDAQ) is $6.05.
VERASTEM INC (VSTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of VERASTEM INC (VSTM:NASDAQ) since the previous trading day is $-0.47.
VERASTEM INC (VSTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of VERASTEM INC (VSTM:NASDAQ) since the previous trading day is -7.2086%.
What is the most recent average sentiment score for VERASTEM INC (VSTM:NASDAQ)?
The most recent average sentiment score for VERASTEM INC (VSTM:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for VERASTEM INC (VSTM:NASDAQ)?
The most recent sentiment for VERASTEM INC (VSTM:NASDAQ) is .
SEC-8K** Filing Available For VERASTEM INC (VSTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.